Ekso Bionics Holdings, INC 8-K filings

Ekso Bionics reported record quarterly sales of $5.0 million in the second quarter of 2024, alongside a gross margin of 53%.

Ekso Bionics has amended its initial 8-K filing to disclose its decision to hold an annual stockholder advisory vote on executive compensation.

Ekso Bionics held its 2024 Annual Meeting of Stockholders, electing five directors, extending its equity incentive plan, and ratifying its independent auditors.

Ekso Bionics announced its first quarter 2024 financial results, highlighted by a Medicare reimbursement determination and a gross margin of 52%.

Ekso Bionics reported record annual revenue of $18.3 million for 2023, a 42% increase year-over-year, driven by strong demand for its EksoHealth devices.

Ekso Bionics Holdings, Inc. has successfully completed a registered direct offering, raising approximately $4 million through the sale of common stock to institutional investors.